Akademik Veri Yönetim Sistemi
3. Uluslararası Kanser ve İyon Kanalları Kongresi , İstanbul, Türkiye, 16 - 18 Eylül 2021, ss.51
Objectives: The fact that ovarian cancer manifests
itself in the late stage and is characterized by a poor
prognosis, is caused death in the majority of cases.
miRNAs being as the biomarker candidates in
diagnosis, and their use in treatment as the inhibitors
of the molecules mimicking the miRNA showed that
they may be used as the new therapeutic target and
agents. Present study aims to determine the effect of
expresion level of miR-142-3p in ovarian cancer
patients.
Material-Methods: We detected with our group in our
prior study conducted with disconcordant ovarian
cancer twins that many miRNA molecules were
different in ovarian cancer compared with the
molecules in healthy sibling. The expression level of
miR-142-3p that was selected from the miRNAs
detected in the previous study was compared, and
investigated in a wider ovarian cancer group, and in
healthy control group. miR-142-3p expression level
was investigated using the real-time PCR method in
the present study involving 147 patients, and 100
healthy control group. The differences in the
expression levels of miR-142-3p detected in the
peripheral blood lymphocytes of ovarian cancer
patients, and healthy control were statisticaly
evaluated.
Results: The expression level of miR-142-3p was
detected to have increased 3.11 fold in ovarian cancer
patients compared with the levels in healthy controls,
and the difference was statistically significant (p:0.00).
We suggest that this microRNA showing high
expression promoted the oncogenesis of ovarian cells
by behaving such an oncogene. miR-142-3p expression
level, and the clinical data,diagnosis, and family
histories were analysed in details.
Conclusions: These results suggest that miR-142-3p
that was found significantly increased in the peripheral
blood samples of ovarian cancer patients compared
with the healthy controls might be used as a sensitive,
noninvasive biomarker in the early diagnosis, and
treatment and follow up of ovarian cancer.